VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients

Extranodal NK/T-cell Lymphoma Clinical Trial

Official title:

A Phase 2 Study to Evaluate the Efficacy and Safety of Postremission Therapy Using VT-EBV-N in EBV Positive Extranodal NK/T Cell Lymphoma Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03671850
• Other study ID #: VT-EBV-201
• Status: Recruiting
• Phase: Phase 2
• Start date: April 9, 2019
• Est. completion date: June 3, 2024

Study information

• Verified date: March 2022
• Source: ViGenCell Inc.
• Contact: Dae-Hee Sohn
• Phone: 82-70-4348-7527
• Email: goriest[@]vigencell.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study aims to evaluate the efficacy and safety of VT-EBV-N (EBV-CTL) administration in ENKL patients after complete remission (CR). This is to prove the effect of VT-EBV-N (EBV-CTL) in prevention of ENKL relapse compared to placebo, by checking the primary endpoint of DFS rate (disease free survival, no relapse or death after randomization) at 2 years (103 weeks) for the last subject enrolled. 50% of the subjects will be administered VT-EBV-N (EBV-CTL), while the remaining subjects will be administered a placebo.

Description:

NK/T-cell lymphoma is a malignant tumor originating in NK cells and T lymphocytes. ENKL is associated with Epstein-Barr virus (EBV) infection and typically occurs in the nasal area, being termed ENKL, nasal type.EBV is a common virus in the herpes family. EBV infection in patients with lowered immunity such as those with Acquired Immune Deficiency Syndrome or those taking immunosuppressants after bone marrow transplant may induce lymphoproliferative diseases or cancer.

VT-EBV-N (EBV-CTL) is a cytotoxicity T lymphocyte (CTL) targeting EBV expressed tumor cells indicated for ENKL. Antigen-presenting cells derived from the patient's own blood is used to activate T-cells in a test tube to recognize EBV, which are then expanded in vitro and infused into the patient's body. Targeted immunotherapy using EBV-CTL is a safe form of treatment that can improve long-term disease-free survival rates by boosting antitumor immunity without affecting other tissues apart from tumor cells.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: June 3, 2024
• Est. primary completion date: December 4, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 75 Years

Eligibility

Inclusion Criteria:

1. EBV positive extranodal NK/T cell lymphoma (ENKL) patients pathologically confirmed according to WHO classification at first diagnosis

2. Patients whose complete remission (CR) has been confirmed within 6 months before screening and maintained, presenting high risk of relapse due to one or more of the following 1) Patients who are EBV detectable at initial diagnosis, with one or more of the following high risk factors 60 years of age or older, Ann Arbor stage II ~ IV, non-nasal type disease, local invasiveness (defined with T3 or T4), elevated LDH (> upper limit of normal)) 2) Patients confirmed to have EBV DNAemia (> 2000 copies/ml) during or after treatment 3) Patients who achieved remission from secondary or greater remission induction therapy after the failure of primary remission induction, or achieved remission after relapse

3. 19 years and above to 75 years and below

4. Patients with ECOG performance criteria score of 0 to 2

5. Patients with acceptable hematopoietic function (ANC = 1.5 x 109 /L, PLT = 100 x 109 /L, Hb = 9 g/dL)

6. Patients with acceptable liver function (total bilirubin < 2 x upper limit of normal, AST/ALT < 3 x upper limit of normal)

7. Patients with renal function of eGFR > 50 or better

8. Patients with life expectancy of 6 or longer

9. Patients who have agreed to use two different types of birth control during the study period (Females of childbearing age or within 2 years after menopause have to show negative results in urine pregnancy test) (E.g., dual contraception using oral contraceptives, contraceptive implant, contraceptive injection, or contraceptive patch combined with intrauterine device, spermicide foam or gel, contraceptive film, vaginal diaphragm, cervical cap, condom, etc.)

10. Patients who have voluntarily given written consent to participate in this study

Exclusion Criteria:

1. Other pathological classifications of nasal cavity lymphoma than ENKL at initial diagnosis

2. Patients with ENKL that has invaded the central nervous system

3. Patients in PR, SD or PD state, not complete remission (CR)

4. Patients who cannot generate EBV-CTL

5. Patients who have received allogeneic stem cell transplantations

6. Patients with severe or uncontrolled medical disorders(diabetes exceeding HbA1C9%, severe hypertension exceeding 180/110 mmHg, heart failure of NYHA class ? or ?, myocardial infarction diagnosed within 6 months prior to screening)

7. Patients with apparent infection (HIV infection, chronic hepatitis B, chronic hepatitis C, active tuberculosis, etc.)

8. Patients with malignant tumors or previous history of malignant tumors except completely recovered non-melanoma skin cancer or stage 0 (in situ) cervical carcinoma

9. Patients currently receiving treatment for ENKL such as chemotherapy, hormone therapy, or immunotherapy

10. Patients with hypersensitivity to the investigational product or pretreatment products, including cryoprotectants

Related Conditions & MeSH terms

• Extranodal NK/T-cell Lymphoma
• Lymphoma
• Lymphoma, Extranodal NK-T-Cell
• Lymphoma, T-Cell

Intervention

Biological:
• VT-EBV-N
Epstein-barr virus human cytotoxic T lymphocytes (EBV-CTL)

Other:
• Placebo
Peripheral blood mononuclear cell, PBMC

Locations

Country	Name	City	State
Korea, Republic of	Inje University Busan Paik Hospital	Busan
Korea, Republic of	Keimyung University Daegu Dongsan Hospital	Daegu
Korea, Republic of	Hallym Univ. Medical Center	Gyeonggi-do
Korea, Republic of	Chonnam National University Hwasun Hospital	Hwasun
Korea, Republic of	Konkuk University Medical Center	Seoul
Korea, Republic of	Seoul National University Hospital	Seoul
Korea, Republic of	Seoul St.Mary's Hospital	Seoul
Korea, Republic of	Severance Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
ViGenCell Inc.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	No relapse or death due to any reason after randomization		Randomization (8 weeks before administration) ~ 116 weeks after treatment period
Secondary	No death after randomization		Randomization (8 weeks before administration) ~ 116 weeks after treatment period
Secondary	No relapse or death due to any reason after randomization		Randomization (116 weeks after treatment period) ~